IGC — IGC Pharma, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1326205 ·
Last close
$0.30
Market Cap
$31.08M
52W High
$0.31
52W Low
$0.24
ADV30
697,409
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 317,000 | 55,000 | -2,458,000 | -2,402,000 | 9,185,000 | 207,000 | 3,064,000 |
| Dec 2025 | 350,000 | 44,000 | -2,941,000 | -726,000 | 9,712,000 | 900,000 | 2,289,000 |
| Sep 2025 | 191,000 | 99,000 | -2,899,000 | -1,821,000 | 9,743,000 | 1,105,000 | 1,651,000 |
| Jun 2025 | 328,000 | 154,000 | -1,905,000 | -1,599,000 | 7,943,000 | 454,000 | 1,865,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,943,000
Investing CF
$-192,000
Financing CF
$5,935,000
CapEx
$-823,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.08
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-127,292,000
Inventory
$638,000
Receivables
$101,000
ST Investments
$28,000
EBIT TTM
$-10,203,000
Pretax Income TTM
$-6,548,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,106,000
EBITDA
$-7,524,000
Free Cash Flow
$-2,521,375
Enterprise Value
$32,570,274
Total Cash
$354,000
Total Debt
$1,082,000
Shares Out
103,384,008
Trailing EPS
$-0.06
Book Value
$0.06
ROE
-83.3%
ROA
-50.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2025 | 1,271,000 | -7,446,000 | -7,121,000 | 8,747,000 | 2,417,000 | — | -4,065,000 |
| Mar 2024 | 1,345,000 | -9,798,000 | -13,000,000 | 9,902,000 | 2,581,000 | — | -5,199,000 |
| Mar 2023 | 911,000 | -11,571,000 | -11,506,000 | 17,178,000 | 2,267,000 | — | -7,047,000 |
| Mar 2022 | 397,000 | -15,428,000 | -15,016,000 | 26,834,000 | 2,942,000 | — | -7,462,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.09
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $0.50 · spot: $0.30 · call volume: 42 · put volume: 300
Expected Move to 2027-02-19:
±$0.52
(173.33%) —
implied range
$-0.22 –
$0.82
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RMTI | ROCKWELL MEDICAL, INC. | $31.84M | $7.90 | — |
| BCTX | BriaCell Therapeutics Corp. | $30.10M | $3.46 | — |
| KYNB | KYNTRA BIO, INC. | $32.31M | $7.98 | — |
| NNVC | NANOVIRICIDES, INC. | $32.38M | $1.27 | — |
| ACTU | ACTUATE THERAPEUTICS, INC. | $29.54M | $1.23 | — |
News headlines (Yahoo Finance, 1h cache)
IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout
2026-08-11 12:30 · Yahoo
IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign
2026-07-29 12:30 · Yahoo
IGC Pharma to Showcase AI Portfolio at AAIC 2026, Including AHA Platform That Reduced Alzheimer's Data Harmonization Time by 90% in Representative Workflow
2026-07-09 13:00 · Yahoo
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
2026-06-02 12:30 · Yahoo
IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase
2026-04-28 16:15 · Yahoo
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
2026-04-22 12:30 · Yahoo
IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia
2026-04-20 12:30 · Yahoo
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
2026-04-14 12:30 · Yahoo
IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease
2026-04-07 12:00 · Yahoo
IGC Pharma's AHA Agentic AI Platform Reduces Alzheimer's Data Harmonization Time by 90% in Representative Workflow
2026-06-23 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.